Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible, P2Y12 receptor antagonist used to prevent thrombotic events.
## Primary Indications
* In combination with aspirin for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI).
* In combination with aspirin for the prevention of thrombotic events in patients with acute coronary syndrome (ACS).
## Adult Dosing
* **ACS:**
* *Loading Dose:* 180 mg orally once.
* *Maintenance Dose:* 90 mg orally twice daily for 12 months.
* Following the initial 12 months of treatment for ACS, ticagrelor 90 mg twice daily may be continued for secondary prevention in select patients. Dosing after 12 months should be individualized based on patient risk for ischemic events and bleeding.
* **History of MI (≥ 1 year ago):**
* 60 mg orally twice daily.
* For patients who have had an MI at least 1 year ago and are treated with ticagrelor 90 mg twice daily for ACS, continue ticagrelor 90 mg twice daily. Then, consider reducing the dose to 60 mg twice daily.
* Dosing beyond 12 months should be individualized.
## Pediatric Dosing
No established pediatric dosing for ticagrelor.
## Dose Adjustments
No dose adjustments are necessary for patients with mild to moderate renal or hepatic impairment. Use with caution in severe renal or hepatic impairment.
## Contraindications
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Known hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
* **Common:** Dyspnea, bradycardia, bleeding (including bruising, epistaxis, hematuria, gastrointestinal bleeding, and serious/fatal bleeding).
* **Less Common:** Ventricular pauses, syncope, hyperuricemia, increased serum creatinine.
## Key Drug Interactions
* **CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin, ritonavir):** May increase ticagrelor plasma concentrations, increasing the risk of bleeding. Avoid concomitant use or use with caution.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** May decrease ticagrelor plasma concentrations. Monitor for reduced efficacy.
* **Aspirin:** Concurrent use is indicated for ACS and post-MI. However, prolonged use of aspirin beyond the dose recommended for ticagrelor therapy may increase bleeding risk.
* **Other Antiplatelets or Anticoagulants (e.g., clopidogrel, warfarin, heparin):** Increased risk of bleeding. Use with caution.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for dyspnea, particularly in patients with pre-existing pulmonary conditions.
* Monitor for bradycardia.
* Electrolytes and renal function may be monitored periodically, especially in patients with risk factors for electrolyte abnormalities or renal dysfunction.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, meaning its effect can be reversed upon discontinuation, unlike clopidogrel.
* Dyspnea is a common side effect and is usually mild and transient; it does not typically require discontinuation of the drug.
* Consider discontinuation of ticagrelor 5-7 days prior to elective surgery if possible, depending on the surgical procedure and bleeding risk.
* Ticagrelor should not be taken with aspirin doses higher than 100 mg daily, except in the context of ACS.
***
*Disclaimer: This information is intended for educational purposes and is not a substitute for professional medical advice. Always consult with a qualified healthcare provider to determine the appropriateness of any medication for your specific condition. Verify current prescribing information from the manufacturer's package insert.*
